{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:36:16Z","timestamp":1784633776522,"version":"3.55.0"},"reference-count":165,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T00:00:00Z","timestamp":1465776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Trasher Research Foundation","award":["TRF11939"],"award-info":[{"award-number":["TRF11939"]}]},{"name":"UCSF John A. Watson Faculty Scholars Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Invasive aspergillosis (IA) is a disease of increasing importance in pediatrics due to growth of the immunocompromised populations at risk and improvements in long-term survival for many of these groups. While general principles of diagnosis and therapy apply similarly across the age spectrum, there are unique considerations for clinicians who care for children and adolescents with IA. This review will highlight important differences in the epidemiology, clinical manifestations, diagnosis, and therapy of pediatric IA.<\/jats:p>","DOI":"10.3390\/jof2020019","type":"journal-article","created":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T10:29:22Z","timestamp":1465813762000},"page":"19","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pediatric Invasive Aspergillosis"],"prefix":"10.3390","volume":"2","author":[{"given":"Rachel","family":"Wattier","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Infectious Diseases and Global Health, University of California-San Francisco, 550 16th St, 4th Floor, Box 0434, San Francisco, CA 94143, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Ramirez-Avila","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Infectious Diseases and Global Health, University of California-San Francisco, 550 16th St, 4th Floor, Box 0434, San Francisco, CA 94143, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/322606","article-title":"Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997","volume":"33","author":"McNeil","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.mph.0000155861.38641.ca","article-title":"Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution","volume":"27","author":"Rosen","year":"2005","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/MPH.0b013e3181acd956","article-title":"Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: A retrospective single centre study","volume":"31","author":"Rubio","year":"2009","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MPH.0000000000000159","article-title":"Invasive aspergillosis in children with acute leukemia at a resource-limited oncology center","volume":"37","author":"Jain","year":"2015","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jpids\/piu074","article-title":"A prospective, international cohort study of invasive mold infections in children","volume":"4","author":"Wattier","year":"2015","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/MPH.0000000000000389","article-title":"Improvement in the outcome of invasive aspergillosis in a pediatric hematology department: A 10-Year review","volume":"37","author":"Domenech","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1542\/peds.2005-1161","article-title":"Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000","volume":"117","author":"Zaoutis","year":"2006","journal-title":"Pediatrics"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/00006454-199702000-00010","article-title":"Invasive aspergillosis in human immunodeficiency virus-infected children","volume":"16","author":"Shetty","year":"1997","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1286","DOI":"10.1542\/peds.2007-2117","article-title":"Pediatric invasive aspergillosis: A multicenter retrospective analysis of 139 contemporary cases","volume":"121","author":"Burgos","year":"2008","journal-title":"Pediatrics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1399-3046.2008.01056.x","article-title":"Invasive mold infections in iatrogenically immunocompromised children: An eight-yr review","volume":"13","author":"Hawkes","year":"2009","journal-title":"Pediatr. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/0961203312442752","article-title":"Invasive aspergillosis: A severe infection in juvenile systemic lupus erythematosus patients","volume":"21","author":"Silva","year":"2012","journal-title":"Lupus"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/clinids\/22.6.1102","article-title":"Primary cutaneous aspergillosis in neonates: Case report and review","volume":"22","author":"Papouli","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1086\/313445","article-title":"Aspergillosis in children with cancer: A 34-year experience","volume":"29","author":"Abbasi","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/INF.0000000000000875","article-title":"Invasive fungal infections in pediatric acute myelogenous leukemia","volume":"34","author":"Ducassou","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00006454-200203000-00013","article-title":"Infections diagnosed in the first year after pediatric stem cell transplantation","volume":"21","author":"Benjamin","year":"2002","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/cid\/ciu1154","article-title":"Common severe infections in chronic granulomatous disease","volume":"60","author":"Marciano","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jaci.2010.01.047","article-title":"Invasive fungal disease in autosomal-dominant hyper-IgE syndrome","volume":"125","author":"Vinh","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1469-0691.2010.03289.x","article-title":"Invasive fungal infections in congenital immunodeficiencies","volume":"16","author":"Antachopoulos","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jinf.2012.08.003","article-title":"Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry","volume":"65","author":"Steinbach","year":"2012","journal-title":"J. Infect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/00006454-199308000-00009","article-title":"Invasive Aspergillus infections in a pediatric hospital - a 10-year review","volume":"12","author":"Walmsley","year":"1993","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jpids\/pis042","article-title":"Invasive mold infections in pediatric cancer patients reflect heterogeneity in etiology, presentation, and outcome: A 10-year, single-institution, retrospective study","volume":"1","author":"Georgiadou","year":"2012","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1018","DOI":"10.1097\/MD.0000000000001018","article-title":"Cutaneous invasive aspergillosis: Retrospective multicenter study of the French Invasive-Aspergillosis Registry and literature review","volume":"94","author":"Bernardeschi","year":"2015","journal-title":"Medicine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: Systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3346\/jkms.2015.30.8.1121","article-title":"Clinical features and prognosis of invasive pulmonary aspergillosis in Korean children with hematologic\/oncologic diseases","volume":"30","author":"Han","year":"2015","journal-title":"J. Korean Med. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1439-0507.2007.01449.x","article-title":"Invasive aspergillosis in a paediatric haematology department: A 15-year review","volume":"51","author":"Crassard","year":"2008","journal-title":"Mycoses"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/08880018.2010.481704","article-title":"Invasive respiratory aspergillosis is a treatable disease with early diagnosis and aggressive therapy","volume":"27","author":"Cakir","year":"2010","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1439-0507.1999.00496.x","article-title":"Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival","volume":"42","author":"Groll","year":"1999","journal-title":"Mycoses"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00043426-200304000-00004","article-title":"Prolonged survival after invasive aspergillosis: A single-institution review of 11 cases","volume":"25","author":"Wright","year":"2003","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00431-007-0527-7","article-title":"Fungal infections in primary immunodeficiencies","volume":"166","author":"Antachopoulos","year":"2007","journal-title":"Eur. J. Pediatr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/pbc.24363","article-title":"Aspergillus galactomannan antigen assay and invasive aspergillosis in pediatric cancer patients and hematopoietic stem cell transplant recipients","volume":"60","author":"Choi","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1525-1470.2002.00203.x","article-title":"Neonatal primary cutaneous aspergillosis: Case report and review of the literature","volume":"19","author":"Woodruff","year":"2002","journal-title":"Pediatr. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Rogdo, B., Kahlert, C., Diener, P.A., and Micallef, J. (2014). Primary cutaneous aspergillosis in a preterm neonate. BMJ Case Rep., 2014.","DOI":"10.1136\/bcr-2014-204752"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamapediatrics.2015.1359","article-title":"A crusted papule in a premature neonate. Cutaneous fungal infection","volume":"169","author":"Simpson","year":"2015","journal-title":"JAMA Pediatr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mmcr.2014.02.001","article-title":"Screening of the central nervous system in children with invasive pulmonary aspergillosis","volume":"4","author":"Broenen","year":"2014","journal-title":"Med. Mycol. Case Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/tid.12445","article-title":"Aspergillus thyroiditis: First antemortem case diagnosed by fine-needle aspiration culture in a pediatric stem cell transplant patient","volume":"17","author":"Badawy","year":"2015","journal-title":"Transpl. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1040","DOI":"10.1016\/j.ijid.2010.08.005","article-title":"Aspergillus endocarditis: A review of the literature","volume":"14","author":"Kalokhe","year":"2010","journal-title":"Int. J. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jinf.2013.12.008","article-title":"Aspergillus osteomyelitis: Epidemiology, clinical manifestations, management, and outcome","volume":"68","author":"Gamaletsou","year":"2014","journal-title":"J. Infect."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/INF.0000000000001015","article-title":"Prognostic factors in the outcome of invasive fungal sinusitis in a pediatric population","volume":"35","author":"Green","year":"2016","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/pbc.23005","article-title":"Invasive fungal infections in pediatric oncology","volume":"56","author":"Mor","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) C","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.bbmt.2014.04.019","article-title":"A comparison of bronchoalveolar lavage versus lung biopsy in pediatric recipients after stem cell transplantation","volume":"20","author":"Qualter","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole resistance in Aspergillus fumigatus: Can we retain the clinical use of mold-active antifungal azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/INF.0b013e3180616cbb","article-title":"Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients","volume":"26","author":"Steinbach","year":"2007","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3855\/jidc.2110","article-title":"Diagnostic potential of nested PCR, galactomannan EIA, and beta-D-glucan for invasive aspergillosis in pediatric patients","volume":"6","author":"Badiee","year":"2012","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jpids\/pis044","article-title":"Galactomannan antigen testing for diagnosis of invasive aspergillosis in pediatric hematology patients","volume":"1","author":"Fisher","year":"2012","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/INF.0b013e31817197ab","article-title":"Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis","volume":"27","author":"Hayden","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/pbc.20717","article-title":"Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders","volume":"48","author":"Hovi","year":"2007","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/myc.12048","article-title":"Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies","volume":"56","author":"Jha","year":"2013","journal-title":"Mycoses"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3109\/08880018.2014.981900","article-title":"Serum galactomannan screening for diagnosis of invasive pulmonary aspergillosis in children after stem cell transplantation or with high-risk leukemia","volume":"32","author":"Gefen","year":"2015","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jmii.2013.12.003","article-title":"Threshold of galactomannan antigenemia positivity for early diagnosis of invasive aspergillosis in neutropenic children","volume":"49","author":"Dinand","year":"2016","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/503427","article-title":"Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis","volume":"42","author":"Pfeiffer","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_54","first-page":"CD007394","article-title":"Galactomannan detection for invasive aspergillosis in immunocompromized patients","volume":"8","author":"Leeflang","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_55","first-page":"CD007394","article-title":"Galactomannan detection for invasive aspergillosis in immunocompromised patients","volume":"12","author":"Leeflang","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/civ555","article-title":"Galactomannan and polymerase chain reaction-based screening for invasive aspergillosis among high-risk hematology patients: A diagnostic meta-analysis","volume":"61","author":"Arvanitis","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1200\/JCO.2012.42.7161","article-title":"Guideline for the management of fever and neutropenia in children with cancer and\/or undergoing hematopoietic stem-cell transplantation","volume":"30","author":"Lehrnbecher","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2002.07.004","article-title":"Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients","volume":"20","author":"Herbrecht","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1439-0507.1998.tb00356.x","article-title":"False-positive results in premature infants with the Platelia Aspergillus sandwich enzyme-linked immunosorbent assay","volume":"41","author":"Siemann","year":"1998","journal-title":"Mycoses"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1128\/JCM.43.8.3925-3931.2005","article-title":"Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity","volume":"43","author":"Ruegebrink","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/j.1469-0691.2010.03336.x","article-title":"Diagnosis of invasive fungal infections in immunocompromised children","volume":"16","author":"Dornbusch","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/cid\/cir897","article-title":"\u03b2-glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: A systematic review and meta-analysis of cohort studies from the third European Conference on Infections in Leukemia (ECIL-3)","volume":"54","author":"Lamoth","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12281-012-0127-5","article-title":"The role of biomarkers for diagnosis of and therapeutic decisions related to invasive aspergillosis in children","volume":"7","author":"Fisher","year":"2013","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Nucci, M., Carlesse, F., Cappellano, P., Varon, A.G., Seber, A., Garnica, M., Nou\u00e9r, S.A., and Colombo, A.L. (2014). Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087784"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1080\/13693780802308454","article-title":"Role of (1->3)-\u03b2-d-glucan in the diagnosis of invasive aspergillosis","volume":"47","author":"Marty","year":"2009","journal-title":"Med. Mycol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/myc.12267","article-title":"Reliability of serum 1,3-\u03b2-d-glucan assay in patients undergoing renal replacement therapy: A review of the literature","volume":"58","author":"Prattes","year":"2015","journal-title":"Mycoses"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/14767058.2012.722716","article-title":"(1-3)-\u03b2-D-glucan levels in candidiasis infections in the critically ill neonate","volume":"26","author":"Goudjil","year":"2013","journal-title":"J. Matern. Fetal. Neonatal Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1128\/JCM.06423-11","article-title":"Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: Analytical and clinical validity","volume":"50","author":"Theunissen","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/INF.0b013e31818f0934","article-title":"The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis","volume":"28","author":"Desai","year":"2009","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/422009","article-title":"Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance","volume":"190","author":"Marr","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1093\/cid\/cir731","article-title":"Invasive mold infections in chronic granulomatous disease: A 25-year retrospective survey","volume":"53","author":"Blumental","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Han, S.B., Kim, S.K., Lee, J.W., Yoon, J.-S., Chung, N.-G., Cho, B., Jeong, D.C., Kang, J.H., Kim, H.-K., and Lee, D.-G. (2015). Serum galactomannan index for early prediction of mortality in immunocompromised children with invasive pulmonary aspergillosis. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-1014-9"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Neofytos, D., Railkar, R., Mullane, K.M., Fredricks, D.N., Granwehr, B., Marr, K.A., Almyroudis, N.G., Kontoyiannis, D.P., Maertens, J., and Fox, R. (2015). Correlation between circulating fungal biomarkers and clinical outcome in invasive aspergillosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129022"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1086\/528714","article-title":"Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: Clinical and research implications","volume":"46","author":"Miceli","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1128\/JCM.00750-11","article-title":"Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients","volume":"50","author":"Bergeron","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ppul.22670","article-title":"Diagnosis of invasive pulmonary aspergillosis in children with bronchoalveolar lavage galactomannan","volume":"48","author":"Merkus","year":"2013","journal-title":"Pediatr. Pulmonol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/JCM.02913-15","article-title":"Diagnostic performance of galactomannan antigen testing in cerebrospinal fluid","volume":"54","author":"Chong","year":"2016","journal-title":"J. Clin. Microbiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1086\/421944","article-title":"\u03b2-d-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome","volume":"39","author":"Odabasi","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1128\/JCM.03567-13","article-title":"Use and limits of (1-3)-\u03b2-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis","volume":"52","author":"Sulahian","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1128\/CVI.00038-10","article-title":"High levels of \u03b2-D-Glucan in immunocompromised children with proven invasive fungal disease","volume":"17","author":"Mularoni","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1128\/JCM.00747-15","article-title":"Beta-D-glucan screening for the detection of invasive fungal disease in children undergoing allogeneic hematopoietic stem cell transplantation","volume":"53","author":"Koltze","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Salvatore, C.M., Chen, T.K., Toussi, S.S., DeLaMora, P., Petraitiene, R., Finkelman, M.A., and Walsh, T.J. (2015). (1\u21923)-\u03b2-d-glucan in cerebrospinal fluid as a biomarker for Candida and Aspergillus infections of the central nervous system in pediatric patients. J. Pediatr. Infect. Dis. Soc.","DOI":"10.1093\/jpids\/piv014"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1128\/CVI.00025-07","article-title":"Quantification of 1,3-beta-D-glucan levels in children: Preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting","volume":"14","author":"Smith","year":"2007","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Mokaddas, E., Burhamah, M.H., Khan, Z.U., and Ahmad, S. (2010). Levels of (1\u21923)-\u03b2-d-glucan, Candida mannan and Candida DNA in serum samples of pediatric cancer patients colonized with Candida species. BMC Infect. Dis., 10.","DOI":"10.1186\/1471-2334-10-292"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/cid\/civ507","article-title":"Aspergillus polymerase chain reaction: Systematic review of evidence for clinical use in comparison with antigen testing","volume":"61","author":"White","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/MPH.0b013e3181b83e77","article-title":"Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients","volume":"31","author":"Armenian","year":"2009","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/myc.12443","article-title":"Biomarker-based diagnostic work-up of invasive pulmonary aspergillosis in immunocompromised paediatric patients - is Aspergillus PCR appropriate?","volume":"59","author":"Buchheidt","year":"2016","journal-title":"Mycoses"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1099\/jmm.0.007393-0","article-title":"Detection of Aspergillus DNA by a nested PCR assay is able to improve the diagnosis of invasive aspergillosis in paediatric patients","volume":"58","author":"Hummel","year":"2009","journal-title":"J. Med. Microbiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/myc.12192","article-title":"Assessment of Aspergillus-specific PCR as a screening method for invasive aspergillosis in paediatric cancer patients and allogeneic haematopoietic stem cell recipients with suspected infections","volume":"57","author":"Reinwald","year":"2014","journal-title":"Mycoses"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1439-0507.2008.01512.x","article-title":"Assessment of the lightcycler PCR assay for diagnosis of invasive aspergillosis in paediatric patients with onco-haematological diseases","volume":"51","author":"Cesaro","year":"2008","journal-title":"Mycoses"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1128\/JCM.00667-15","article-title":"Analytical and clinical evaluation of the PathoNostics AsperGenius assay for detection of invasive aspergillosis and resistance to azole antifungal drugs during testing of serum samples","volume":"53","author":"White","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1128\/JCM.03216-14","article-title":"Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid","volume":"53","author":"Chong","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Reinwald, M., Buchheidt, D., Hummel, M., Duerken, M., Bertz, H., Schwerdtfeger, R., Reuter, S., Kiehl, M.G., Barreto-Miranda, M., Hofmann, W.K., and Spiess, B. (2013). Diagnostic performance of an Aspergillus-specific nested PCR assay in cerebrospinal fluid samples of immunocompromised patients for detection of central nervous system aspergillosis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056706"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1128\/JCM.02387-13","article-title":"Aspergillus PCR-based investigation of fresh tissue and effusion samples in patients with suspected invasive aspergillosis enhances diagnostic capabilities","volume":"51","author":"Reinwald","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Babouee Flury, B., Weisser, M., Prince, S.S., Bubendorf, L., Battegay, M., Frei, R., and Goldenberger, D. (2014). Performances of two different panfungal PCRs to detect mould DNA in formalin-fixed paraffin-embedded tissue: What are the limiting factors?. BMC Infect. Dis., 14.","DOI":"10.1186\/s12879-014-0692-z"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/cid\/ciu725","article-title":"A breath fungal secondary metabolite signature to diagnose invasive aspergillosis","volume":"59","author":"Koo","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s15010-013-0472-5","article-title":"Comparison of a novel Aspergillus lateral-flow device and the Platelia\u00ae galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation","volume":"41","author":"Held","year":"2013","journal-title":"Infection"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/myc.12327","article-title":"Performance of lateral flow device and galactomannan for the detection of Aspergillus species in bronchoalveolar fluid of patients at risk for invasive pulmonary aspergillosis","volume":"58","author":"Miceli","year":"2015","journal-title":"Mycoses"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1997.15.1.139","article-title":"Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery","volume":"15","author":"Caillot","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1034\/j.1600-0455.2002.430310.x","article-title":"Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis","volume":"43","author":"Hauggaard","year":"2002","journal-title":"Acta Radiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF02013825","article-title":"CT of invasive pulmonary aspergillosis in children with cancer","volume":"23","author":"Taccone","year":"1993","journal-title":"Pediatr. Radiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00247-003-0919-4","article-title":"The radiological spectrum of invasive aspergillosis in children: A 10-year review","volume":"33","author":"Thomas","year":"2003","journal-title":"Pediatr. Radiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/cid\/cir122","article-title":"The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts","volume":"52","author":"Georgiadou","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40336-015-0159-2","article-title":"Imaging fungal infections in children","volume":"4","author":"Ankrah","year":"2016","journal-title":"Clin. Transl. Imaging"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1148\/rg.226025029","article-title":"Neuroimaging in pediatric leukemia and lymphoma: Differential diagnosis","volume":"22","author":"Lucaya","year":"2002","journal-title":"Radiographics"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/0971-5851.107104","article-title":"Cerebral Aspergillus infection in pediatric acute lymphoblastic leukemia induction therapy","volume":"33","author":"Prakash","year":"2012","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"ref_107","first-page":"186","article-title":"Patterns of off-label prescribing in the pediatric intensive care unit and prioritizing future research","volume":"20","author":"Czaja","year":"2015","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s10156-011-0357-4","article-title":"Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children","volume":"18","author":"Sunakawa","year":"2012","journal-title":"J. Infect. Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/jac\/dkp196","article-title":"Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation","volume":"64","author":"Kolve","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.inf.0000153183.51258.b8","article-title":"Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections","volume":"24","author":"Wiley","year":"2005","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/00006454-199908000-00010","article-title":"Amphotericin B lipid complex in pediatric patients with invasive fungal infections","volume":"18","author":"Walsh","year":"1999","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00043426-200005000-00009","article-title":"Use of amphotericin B colloidal dispersion in children","volume":"22","author":"Sandler","year":"2000","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.00751-08","article-title":"Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies","volume":"53","author":"Karlsson","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1128\/AAC.00896-10","article-title":"Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.1128\/AAC.00531-11","article-title":"Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults","volume":"55","author":"Driscoll","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00006454-200203000-00015","article-title":"Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children","volume":"21","author":"Walsh","year":"2002","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1128\/AAC.42.2.404","article-title":"Repeated dose pharmacokinetics of an oral solution of itraconazole in infants and children","volume":"42","author":"Ratelle","year":"1998","journal-title":"Antimicrob. Agents Chemother"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/AAC.00454-06","article-title":"Posaconazole plasma concentrations in juvenile patients with invasive fungal infection","volume":"51","author":"Krishna","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"D\u00f6ring, M., M\u00fcller, C., Johann, P.D., Erbacher, A., Kimmig, A., Schwarze, C.P., Lang, P., Handgretinger, R., and M\u00fcller, I. (2012). Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect. Dis., 12.","DOI":"10.1186\/1471-2334-12-263"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1345\/aph.1R775","article-title":"Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer","volume":"47","author":"Bernardo","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10096-015-2340-y","article-title":"Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia","volume":"34","author":"Eikemeier","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s10096-010-0957-4","article-title":"Posaconazole salvage treatment in paediatric patients: A multicentre survey","volume":"29","author":"Lehrnbecher","year":"2010","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1128\/AAC.49.11.4536-4545.2005","article-title":"Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents","volume":"49","author":"Walsh","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1128\/AAC.01027-08","article-title":"Pharmacokinetics and safety of caspofungin in older infants and toddlers","volume":"53","author":"Neely","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/INF.0b013e3181af5a15","article-title":"Safety experience with caspofungin in pediatric patients","volume":"28","author":"Zaoutis","year":"2009","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1128\/AAC.00905-10","article-title":"Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients","volume":"55","author":"Li","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jac\/dkl009","article-title":"Treatment with caspofungin in immunocompromised paediatric patients: A multicentre survey","volume":"57","author":"Groll","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1542\/peds.2008-1158","article-title":"A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients","volume":"123","author":"Zaoutis","year":"2009","journal-title":"Pediatrics"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1128\/AAC.49.8.3317-3324.2005","article-title":"Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients","volume":"49","author":"Seibel","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1128\/AAC.00398-07","article-title":"Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing","volume":"51","author":"Hope","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1097\/INF.0b013e3182127eaf","article-title":"Safety of micafungin in pediatric clinical trials","volume":"30","author":"Arrieta","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/AAC.03736-14","article-title":"Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents","volume":"59","author":"Hope","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jinf.2006.03.003","article-title":"Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis","volume":"53","author":"Denning","year":"2006","journal-title":"J. Infect."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/AAC.50.2.632-638.2006","article-title":"Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections","volume":"50","author":"Benjamin","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation","volume":"15","author":"Groll","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1128\/AAC.48.9.3217-3225.2004","article-title":"In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection","volume":"48","author":"Steinbach","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: A comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system","volume":"182","author":"Groll","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/AAC.42.11.3018","article-title":"Organism-dependent fungicidal activities of azoles","volume":"42","author":"Manavathu","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40262-014-0181-y","article-title":"A physiologically based pharmacokinetic model for voriconazole disposition predicts intestinal first-pass metabolism in children","volume":"53","author":"Zane","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/AAC.01540-12","article-title":"Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients","volume":"57","author":"Bartelink","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/pbc.24262","article-title":"Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis","volume":"60","author":"Choi","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3109\/08880018.2015.1088905","article-title":"The clinical significance of voriconazole therapeutic drug monitoring in children with invasive fungal infections","volume":"32","author":"Kang","year":"2015","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Luong, M.-L., Al-Dabbagh, M., Groll, A.H., Racil, Z., Nannya, Y., Mitsani, D., and Husain, S. (2016). Utility of voriconazole therapeutic drug monitoring: A meta-analysis. J. Antimicrob. Chemother.","DOI":"10.1093\/jac\/dkw099"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: A randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1442-200X.2010.03321.x","article-title":"Voriconazole-induced QT interval prolongation and torsades de pointes","volume":"53","author":"Aypar","year":"2011","journal-title":"Pediatr. Int."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/INF.0b013e3182566311","article-title":"Voriconazole-induced phototoxicity in children","volume":"31","author":"Bernhard","year":"2012","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1128\/AAC.00068-13","article-title":"Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate","volume":"57","author":"Huitema","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaad.2009.09.033","article-title":"Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole","volume":"62","author":"Cowen","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/cid\/ciq188","article-title":"Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy","volume":"52","author":"Wermers","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/pbc.25283","article-title":"Elevated fluoride levels and periostitis in pediatric hematopoeitic stem cell transplant recipients receiving long-term voriconazole","volume":"62","author":"Tarlock","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1345\/aph.1Q456","article-title":"Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients","volume":"46","author":"Matthias","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_160","unstructured":"Merck Sharp & Dohme Corp A study of the safety, tolerance, and pharmacokinetics of oral posaconazole in immunocompromised children. In ClinicalTrials.gov. Bethesda(MD): National Library of Medicine (US), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01716234 NLM Identifier: NCT01716234."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: A new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1182\/blood-2005-05-1775","article-title":"Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation","volume":"106","author":"Perruccio","year":"2005","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.critrevonc.2015.10.005","article-title":"Adoptive transfer of Aspergillus-specific T cells as a novel anti-fungal therapy for hematopoietic stem cell transplant recipients: Progress and challenges","volume":"98","author":"Papadopoulou","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/2\/2\/19\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:25:21Z","timestamp":1760210721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/2\/2\/19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,13]]},"references-count":165,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,6]]}},"alternative-id":["jof2020019"],"URL":"https:\/\/doi.org\/10.3390\/jof2020019","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,13]]}}}